Navigation Links
Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week
Date:1/31/2011

BEVERLY HILLS, Calif., Jan. 31, 2011 /PRNewswire/ -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX™ joint health formula, launched commercially in December 2010.  Specifically, the study found that reduction of pain was statistically significant after as little as one week of ERGOFLEX use.  Similar improvements were seen with range of motion.  Benefits continued during the six weeks subjects took ERGOFLEX, and for some the benefits persisted during the subsequent six-week washout period.

ERGOFLEX is the only joint health complex containing the powerful antioxidant L-Ergothioneine (ERGO) and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health. It is the first in a series of products built around the ERGO platform that are planned by OXIS.  

"These powerful and statistically significant final results strongly suggest that ERGOFLEX can provide significant quick and lasting relief from mild-to-moderate joint pain while improving range of motion, which results in an improved quality of life," said Bernie Landes, President of OXIS International.  "These clinically demonstrated results represent an important breakthrough for those tens of millions of Americans who suffer with chronic joint pain and diminished range of motion.  While most joint pain products only address the symptoms, ERGOFLEX targets and relieves oxidative stress, which frequently is the underlying cause of joint ailments. It also provides a suite of extensively researched natural ingredients that help maintain the structural integrity of joints and relieve pain."

The study included 12 subjects taking ERGOFLEX at the recommended dose of two capsules per-day for six weeks, followed by a six-week washout period.  At study start the participants exhibited mild-to-moderate chronic pain affecting range of motion in several areas, including neck, shoulders, arms, lower back, hips and knees.  The participants also had not consumed other joint relief supplements or juices with high antioxidant content for a period of two months prior to study intake.

Subjects were examined in the lab at study start (day 0) and at weeks one, six and 12; in addition, questionnaires were conducted weekly via phone to monitor health changes.  Each subject was evaluated using 27 distinct range-of-motion measurements conducted on the major areas of discomfort and on the body's entire vertical axis.  The assessments were performed by Dr. David Ager, DC at Cascade Spine and Rehabilitation clinic, using the J-Tech dual digital inclinometry.  All 12 subjects completed the 12-week study.

Based on the results from this initial trial, OXIS plans to design and implement a placebo-controlled, randomized clinical trial with ERGOFLEX.

OXIS has previously announced the First World Congress on Ergothioneine to be held at UCLA in July 2011.  This study reflects OXIS's continuing commitment to building its business on a foundation of sound science.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. Ergothioneine can also be sold to the cosmetics markets as well as the functional food and beverage markets.  For more information, please visit www.oxis.com.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may," "potential" or the negative of those words or other similar expressions words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risks and uncertainties inherent in our business, including, without limitation the risks of obtaining possibly required regulatory approvals, the timing of product introductions, the level of market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing and the Company's ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q.  Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.


'/>"/>
SOURCE OXIS International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017   Protein Sciences Corporation ... Flublok® Influenza Vaccine , announced today that they ... Influenza Vaccine Introduction (PIVI) and the Mongolian Ministry of ... of the flu.  The doses of Flublok have been ... Mongolia for health care workers, pregnant women, ...
(Date:2/22/2017)... 22, 2017 The Senior Care Pharmacy Coalition ... and House of Representatives that will curtail the ability ... -- from extracting retroactive direct and indirect remuneration (DIR) ... pharmacies and the Medicare program. S. 413, ... and Jon Tester (D-MT), and House companion ...
(Date:2/22/2017)... , Feb 22, 2017 Research ... Temperature Monitoring Devices Market (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis ... ... Monitoring Devices Market is forecasted to grow at a CAGR of ... the rising prevalence of infectious diseases along with surging demand of ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Using the power of the internet, ... online checklist. Over a period of just 24 months, thousands of individuals interested in ... checklist called T.A.D. , “The internet is not getting quieter. In fact it’s becoming ...
(Date:2/22/2017)... ... 22, 2017 , ... Bellus Medical, a leader in medical ... delivery of Platelet Rich Plasma (PRP). PRP systems are used by physicians in ... synthesis and provide a faster and more efficient healing process. There are many ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the Athens ... in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth of ... the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet wood ...
(Date:2/22/2017)... ... February 22, 2017 , ... In ... many different solutions on the market, it is easy to start feeling frustrated ... Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, There ...
(Date:2/21/2017)... , ... February 22, 2017 , ... Author Michèle Wolff ... valuable for every household and family to know all about it for optimal health. ... with the release of “ Detox, Digestive and Wellness Solutions ” (published by Balboa ...
Breaking Medicine News(10 mins):